GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Sihuan Bioengineering Co 000518.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

3.04

-1.30%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jiangsu Sihuan Bioengineering Co

Its shares trade on Shenzhen under the ticker 000518.SZ. It has been listed since 8 September 1993. In the fiscal year to 31 December 2025, it reported revenue of CN¥344.4m and a net loss of CN¥37.1m. At that date it held total assets of CN¥494.0m and shareholders' equity of CN¥334.6m.

Jiangsu Sihuan Bioengineering Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Wuxi, Jiangsu. The Company’s main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The firm is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Sept 1993
Employees
250

Leadership

Pay as last reported

  • Mr. Yu GuoChairman of the Board, General Manager, Acting Secretary of the Board, since 2020CN¥350,300
  • Ms. Jie ZhaoChief Financial Officer
  • Mr. Jun WenDirectorCN¥514,400
  • Ms. Wei LiuIndependent DirectorCN¥60,000
  • Ms. Li WangIndependent Director
  • Mr. Liangwei WuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Jiangsu Sihuan Bioengineering Co Ltd employs 250 full-time staff members in Wuxi.
  • The company manufactures interleukin and erythropoietin for the global pharmaceutical market.
  • Products include G-CSF tablets and bulk drugs for domestic and overseas sales.

Weaknesses

  • The firm operates in the biotechnology sector with a small workforce of 250 employees.
  • Jiangsu Sihuan Bioengineering Co Ltd has a limited product range compared to larger rivals.
  • The company relies on infusion glass bottles and soft bag infusion for distribution.

Opportunities

  • Expanding the sale of healthcare products and syrup to new international markets.
  • Growing demand for granulocyte colony-stimulating factor in the global biotechnology sector.
  • Increasing domestic market share for interleukin and erythropoietin pharmaceutical products.

Threats

  • Intense competition in the Chinese biotechnology industry for bulk drugs and tablets.
  • Regulatory changes affecting the manufacture of infusion glass bottles and soft bag infusion.
  • Economic fluctuations impacting the domestic market for healthcare products and syrup.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.